Covid-19 Treatments

Brazil to receive 2m Hydroxychloroquine doses from U.S.

According to a statement by the White House, the U.S. has sent two million doses of hydroxychloroquine to Brazil. Both Brazil and the U.S. are testing whether the drug is safe and effective for Covid-19 treatment.

Science • Medicine
France stops the use of hydroxychloroquine for Covid-19 treatment

France has revoked a decree that authorised the usage of hydroxychloroquine for Covid-19 treatments. The move comes after the World Health Organization suspended a global drug trial due to safety concerns. Furthermore, a study by the British medical journal The Lancet found the drug to increase mortality rates and frequency of irregular heartbeats in patients.

WHO suspends clinical test for malaria drug hydroxychloroquine
WHO suspends clinical test for malaria drug hydroxychloroquine
Credit: Marcelo Casal/Agencia Brasil

The World Health Organization (WHO) has stopped a clinical trial for hydroxychloroquine due to safety concerns after a paper published in The Lancet showed that people taking the drug were at higher risk of death and heart problems than those that were not.
During a news briefing WHO director-general, Tedros Adhanom Ghebreyesus, stated "This concern relates to the use of hydroxychloroquine and chloroquine in Covid-19,"

Study suggests that plasma transfusions from Covid-19 survivors could boost survival rates of other patients

A study conducted by the Mount Sinai Hospital in New York suggests that a blood transfusion from patients that previously had recovered from Covid-19 could improve the survival rates of other patients. The study compares the health of 39 patients that had received the transfusion with 39 patients who didn't and was published on medRxiv in a preprint state - meaning that it still has to undergo peer-review by other researchers. The study also hasn't been randomized, but according to the researchers the study "does show promise that convalescent plasma is effective" as the research is still going on.

Covid-19: New study links hydroxychloroquine and chloroquine to a greater risk of death

According to a new study published in The Lancet Covid-19 patients with a severe illness caused by the new coronavirus treated with chloroquine or hydroxychloroquine were more likely to die or develop dangerous heart arrhythmias.
"This is the first large-scale study to find statistically robust evidence that treatment with chloroquine or hydroxychloroquine does not benefit patients with COVID-19," co-author Dr Mandeep R. Mehra, executive director of the Brigham and Women's Hospital Center for Advanced Heart Disease in Boston noted in a press release.

Politics • American • US
Trump states he's taking the controversial drug Hydroxychloroquine

On Monday, Trump stated that he has been taking Hydroxychloroquine as a "preventive measure". The drug, which has been used for preventing or treating malaria, has not shown compelling evidence to suggest it's an effective preventive medication in regards to Covid-19. Many health experts, including Dr Rick Bright who recently was fired by the Trump administration, have been warning of the drug's potential health hazards and have now again raised concerns about the president's handling of the drug.

Trump said he's taking the drug because "I think I hear very good things,” and that he gets "a lot of tremendously positive news on the hydroxy".

Science • Medicine
Johnson & Johnson aiming to produce 1 billion doses of Covid-19 vaccines in 2021

Johnson & Johnson, multinational medical and pharmaceutical corporation, said in a statement on Sunday that they "aim to deliver 1 billion (Covid-19) vaccines next year". According to Paul Stoffels, chief scientific officer, the company is starting clinical trials in September and is planning to upscale their manufacturing to be able to start producing the vaccine late this year. Stoffel added “We will have some vaccine available this year, but it will depend on the authorities – the FDA and others – to decide whether it can be used earlier, before efficacy data are available".

Hydroxychloroquine shows no benefit in coronavirus study

A new study published in the New England Journal of Medicine found no evidence of benefit from using Hydroxychloroquine as a treatment for coronavirus infection.
The study that involved 1,376 patients claims the drug did not lower the risk of dying or needing a breathing tube.

Science • Medicine
Remdesivir trial results show efficacy in Covid-19 treatment

The US National Institute of Allergy and Infectious Diseases has been running a trial of Remdesivir on 1,063 randomly assigned patients hospitalised with Covid-19. The group who got the Remdesivir treatment showed a median time of recovery of 11 days, while those who got a placebo averaged on a 15 day recovery. Mortality rate was 8% for the Remdesivir group and 11.6% for the placebo group.